Clinical characteristics, health care resource utilization and direct medical costs of Rotavirus hospitalizations in Spain (2013–2018)

ABSTRACT Rotavirus (RV) is the most common cause of severe gastroenteritis (GE) in infants and young children worldwide and is associated with a significant clinical and economic burden. The objective of this study was to analyze the characteristics, healthcare resource utilization and the direct medical costs related to RVGE hospitalizations in Spain. An observational, multicenter, cross-sectional study was conducted from June 2013 to May 2018 at the pediatric departments of 12 hospitals from different Spanish regions. Children under 5 years of age admitted to the hospital with a confirmed diagnosis of RVGE were selected. Data on clinical characteristics, healthcare resource use and costs were collected from patient records and hospital databases. Most children hospitalized for RVGE did not have any previous medical condition or chronic disease. Forty-seven percent had previously visited the Emergency Room (ER), 27% had visited a primary care pediatrician, and 15% had received pharmacological treatment prior to hospital admission due to an RVGE episode. The average length of a hospital stay for RVGE was 5.6 days, and the mean medical costs of RVGE hospitalizations per episode ranged from 3,940€ to 4,100€. The highest direct medical cost was due to the hospital stay. This study showed a high burden of health resource utilization and costs related to the management of cases of RVGE requiring hospitalization. RV vaccination with high coverage rates should be considered to minimize the clinical and economic impacts of this disease on the health-care system.

[1]  M. Mendizabal,et al.  Rotavirus gastroenteritis hospitalizations in provinces with different vaccination coverage rates in Spain, 2013–2018 , 2021, BMC Infectious Diseases.

[2]  N. Low,et al.  Rotavirus disease and health care utilisation among children under 5 years of age in highly developed countries: A systematic review and meta-analysis. , 2021, Vaccine.

[3]  G. Kang,et al.  Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: A World Health Organization Action Framework , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  N. Low,et al.  Rotavirus disease and health care utilisation among children under 5 years of age in highly developed countries: a systematic review and meta-analysis , 2020, medRxiv.

[5]  D. Nieboer,et al.  Variation in antibiotic prescription rates in febrile children presenting to emergency departments across Europe (MOFICHE): A multicentre observational study , 2020, PLoS medicine.

[6]  B. Standaert,et al.  Fifteen years of experience with the oral live-attenuated human rotavirus vaccine: reflections on lessons learned , 2020, Expert review of vaccines.

[7]  J. Vekemans,et al.  Vaccine impact on antimicrobial resistance to inform Gavi, the Vaccine Alliance’s 2018 Vaccine Investment Strategy: report from an expert survey , 2019, F1000Research.

[8]  F. Martinón-Torres,et al.  [What have we learnt about rotavirus in Spain in the last 10 years?] , 2019, Anales de pediatria.

[9]  K. Johansen,et al.  Impact on affected families and society of severe rotavirus infections in Swedish children assessed in a prospective cohort study , 2018, Infectious diseases.

[10]  C. Giaquinto,et al.  Report of the 5th European expert meeting on rotavirus vaccination (EEROVAC) , 2018, Human vaccines & immunotherapeutics.

[11]  M. Bonten,et al.  Rotavirus disease course among immunocompromised patients; 5-year observations from a tertiary care medical centre. , 2017, The Journal of infection.

[12]  E. Burnett,et al.  Effectiveness of Rotavirus Vaccination: A Systematic Review of the First Decade of Global Postlicensure Data, 2006–2016 , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Díez-Domingo,et al.  Long-term impact of self-financed rotavirus vaccines on rotavirus-associated hospitalizations and costs in the Valencia Region, Spain , 2017, BMC Infectious Diseases.

[14]  G. Kang,et al.  Rotavirus infection , 2017, Nature Reviews Disease Primers.

[15]  J. Arístegui,et al.  Multicenter prospective study on the burden of rotavirus gastroenteritis in children less than 3 years of age in Spain , 2016, BMC Infectious Diseases.

[16]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[17]  J. Arístegui,et al.  Economic and psychosocial impact of rotavirus infection in Spain: a literature review. , 2014, Vaccine.

[18]  F. Martinón-Torres,et al.  Caracterización microbiológica de las gastroenteritis agudas virales atendidas en un servicio de pediatría en un área de alta cobertura vacunal frente a rotavirus , 2014 .

[19]  A. Curns,et al.  Protective association between rotavirus vaccination and childhood seizures in the year following vaccination in US children. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  A. Sánchez-Fauquier,et al.  [Microbiological profile of acute viral gastroenteritis attended in a paediatric department of an area with high vaccine cover against rotavirus]. , 2014, Enfermedades infecciosas y microbiologia clinica.

[21]  Dong Hyun Kim,et al.  Comparison between febrile and afebrile seizures associated with mild rotavirus gastroenteritis , 2013, Seizure.

[22]  C. Giaquinto,et al.  Burden of community-acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review , 2012, BMC Infectious Diseases.

[23]  M. Berger,et al.  Guidelines on acute gastroenteritis in children: a critical appraisal of their quality and applicability in primary care , 2011, BMC family practice.

[24]  A. Garcia-Basteiro,et al.  Hospitalizations due to rotavirus gastroenteritis in Catalonia, Spain, 2003-2008 , 2011, BMC Research Notes.

[25]  F. Martinón-Torres,et al.  Prospective evaluation of indirect costs due to acute rotavirus gastroenteritis in Spain: the ROTACOST study , 2011, BMC pediatrics.

[26]  S. Halperin,et al.  Substantial Morbidity for Hospitalized Children With Community-Acquired Rotavirus Infections: 2005–2007 IMPACT Surveillance in Canadian Hospitals , 2010, The Pediatric infectious disease journal.

[27]  J. Bale,et al.  Rotavirus gastroenteritis and seizures in young children. , 2010, Pediatric neurology.

[28]  F. Martinón-Torres,et al.  Multicenter prospective study analysing the role of rotavirus on acute gastroenteritis in Spain , 2010, Acta paediatrica.

[29]  R. Gil-Prieto,et al.  Hospital-acquired rotavirus infections in Spain over a ten-year period (1998-2007) , 2009, Human vaccines.

[30]  F. Luquero,et al.  [Profile of paediatric admissions and emergencies during an epidemic period of rotavirus in Valladolid [Spain]. Utility of a predictive model]. , 2009, Gaceta sanitaria.

[31]  J. M. E. Bouza,et al.  Perfil de ingresos y urgencias pediátricas en período epidémico de rotavirus en Valladolid: Utilidad de un modelo predictivo , 2009 .

[32]  R. Jiménez-García,et al.  Hospitalizations associated with rotavirus gastroenteritis in Spain, 2001–2005 , 2008, BMC public health.

[33]  M. Epstein,et al.  Guidelines for good pharmacoepidemiology practices (GPP) , 2008 .

[34]  C. Giaquinto,et al.  Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study. , 2007, The Journal of infectious diseases.

[35]  P. Rhodes,et al.  A Case-Control Study to Determine Risk Factors for Hospitalization for Rotavirus Gastroenteritis in U.S. Children , 2006, The Pediatric infectious disease journal.

[36]  I. Oyagüez,et al.  Burden of hospitalizations attributable to rotavirus infection in children in Spain, period 1999-2000. , 2004, Vaccine.

[37]  C. Sierra Salinas,et al.  Gastroenteritis aguda , 2001, Anales de Pediatría.